Genetic evidence for the effects of glucokinase activation on frailty‐related outcomes: A Mendelian randomisation study
Aims
We aimed to use the Mendelian randomisation (MR) design to investigate the potential causal effects of glucokinase (GK) activation on frailty‐related outcomes and to explore the potential mediating effects of metabolic and inflammatory biomarkers.
Materials and Methods
Seventeen independent single‐nucleotide polymorphisms (SNPs) located within the GCK gene and significantly correlated with the glycated haemoglobin (HbA1c) level were used as genetic proxies for the effect of GK activation. We employed two‐sample MR analysis to assess the relationship between genetically proxied GK activation and multifactorial frailty‐related outcomes (frailty index, grip strength, walking pace, appendicular lean mass [ALM] and telomere length) We also explored the potential mediating effects using two‐step MR.
Results
Genetically proxied GK activation was significantly associated with a lower frailty index (beta: −0.161 per 1% decrease in HbA1c level due to GK activation, 95% confidence interval: −0.282 to −0.040, false discovery rate‐adjusted p = 0.011). Additionally, GK activation showed significant associations with increased grip strength, higher ALM, faster walking pace and longer telomere length. GK activation also demonstrated a significant indirect effect on total grip strength and telomere length by reducing C‐reactive protein levels (proportion of mediation: 6.79% to 8.21%).
Conclusion
Our study provides genetic evidence supporting the causal effects of GK activation on lowering the risk of frailty. These findings suggest that GK activators (GKAs) may aid in the management of frailty and sarcopaenia in people with diabetes; however, future randomized controlled trials are necessary to validate these results and establish their clinical applicability.
